Inventor · disambiguated record
Tea Gunde
Also filed as: GUNDE TEA
25 granted patents·15 pending applications·170 citations·filing 2005–2024
94Inventor score
Files withNumab Therapeutics AG18ESBATECH ALCON BIOMED RES UNIT6NUMAB AG5TILLOTTS PHARMA AG4NOVARTIS AG2
Top patents by PatentIndex Score
40 records- 0197US9090684B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2012·Granted Jul 28, 2015·54 cites·8 claims
- 0295US8673310B2Stable and soluble antibodies inhibiting TNFαBORRAS LEONARDO·Filed 2009·Granted Mar 18, 2014·36 cites·12 claims
- 0395US8349322B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2009·Granted Jan 8, 2013·31 cites·10 claims
- 0493US10590193B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2017·Granted Mar 17, 2020·9 cites·14 claims
- 0593US9873737B2Stable and soluble antibodies inhibiting VEGFESBATECH ALCON BIOMED RES UNIT·Filed 2015·Granted Jan 23, 2018·10 cites·7 claims
- 0691US9422366B2Stable and soluble antibodies inhibiting TNF alphaESBATECH ALCON BIOMED RES UNIT·Filed 2013·Granted Aug 23, 2016·12 cites·24 claims
- 0790US10100111B2Stable and soluble antibodies inhibiting TNF alphaESBATECH ALCON BIOMED RES UNIT·Filed 2016·Granted Oct 16, 2018·7 cites·21 claims
- 0886US11459383B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2017·Granted Oct 4, 2022·5 cites·20 claims
- 0979US12209122B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2022·Granted Jan 28, 2025·0 cites·26 claims
- 1074US12043663B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2022·Granted Jul 23, 2024·0 cites·16 claims
- 1174US10077312B2CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseasesNUMAB AG·Filed 2014·Granted Sep 18, 2018·3 cites·18 claims
- 1274US7566528B2Method for the identification and/or validation of receptor tyrosine kinase inhibitorsESBATECH AG·Filed 2005·Granted Jul 28, 2009·2 cites·13 claims
- 1373US11319371B2Anti-CD3 antibodiesNumab Therapeutics AG·Filed 2018·Granted May 3, 2022·1 cites·16 claims
- 1470US2025066482A1Antibodies targeting pdl1 and methods of use thereofNumab Therapeutics AG·Filed 2024·Application pending·0 cites
- 1570US2020172608A1Stable and soluble antibodies inhibiting vegfNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1668US11578123B2Stable and soluble antibodies inhibiting TNFαNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·0 cites·17 claims
- 1762US2022403028A1Novel anti-cd3 antibodiesNumab Therapeutics AG·Filed 2022·Application pending·0 cites
- 1858US12077588B2Antibodies targeting PDL1 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Sep 3, 2024·0 cites·28 claims
- 1956US2025282880A1Antibody variable domains that bind il-4rNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 2056US2024043547A1Antibody variable domains that bind il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 2155US2018282419A1Bispecific Constructs and Their Use in the Treatment of Various DiseasesNumab Therapeutics AG·Filed 2018·Application pending·0 cites
- 2254US2023391882A1Combination treatmentNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 2353US12209133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2019·Granted Jan 28, 2025·0 cites·25 claims
- 2451US12202911B2Multispecific antibody comprising CD137 binding domain and PDL1 binding domainNumab Therapeutics AG·Filed 2018·Granted Jan 21, 2025·0 cites·3 claims
- 2551US11578133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Feb 14, 2023·0 cites·15 claims
- 2651US2007149535A1Protein kinase inhibitorsONCALIS AG·Filed 2006·Application pending·0 cites
- 2750US12503505B2Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereofNumab Therapeutics AG·Filed 2020·Granted Dec 23, 2025·0 cites·28 claims
- 2850US2025282879A1Multispecific antibodies having specificity for il-4r and il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 2950US2024392003A1Multispecific antibodies having specificity for ror1 and cd3Numab Therapeutics AG·Filed 2022·Application pending·0 cites
- 3049US2023203162A1Multispecific antibodyNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 3145US10975143B2Anti-TNF-α-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2017·Granted Apr 13, 2021·0 cites·20 claims
- 3244US10774140B2Anti-TNFα-antibodies and functional fragments thereofNumab Therapeutics AG·Filed 2017·Granted Sep 15, 2020·0 cites·16 claims
- 3343US10759852B2Anti-TNF-alpha-antibodies and functional fragments thereofNUMAB INNOVATION AG·Filed 2017·Granted Sep 1, 2020·0 cites·17 claims
- 3443US2016090416A1Novel antibodiesNUMAB AG·Filed 2014·Application pending·0 cites
- 3542US12098203B2Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSANumab Therapeutics AG·Filed 2018·Granted Sep 24, 2024·0 cites·25 claims
- 3642US2015329637A1Depletion of il23r expressing cells in the treatment of various diseasesNUMAB AG·Filed 2015·Application pending·0 cites
- 3741US10787508B2Anti-TNFα-antibodies and functional fragments thereofNUMAB INNOVATION AG·Filed 2017·Granted Sep 29, 2020·0 cites·17 claims
- 3841US2017073415A1Novel multispecific molecules and novel treatment methods based on such multispecific moleculesNUMAB AG·Filed 2014·Application pending·0 cites
- 3940US2016368987A1Bispecific constructs and their use in the treatment of various diseasesNUMAB AG·Filed 2014·Application pending·0 cites
- 4038US11365240B2Anti-HSA antibodiesNumab Therapeutics AG·Filed 2018·Granted Jun 21, 2022·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Tea Gunde files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →